- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06464991
Eine Phase-III-Studie zu Eque-cel bei Patienten mit Len-refraktärem RRMM (FUMANBA-03) (FUMANBA-03)
Eine randomisierte, kontrollierte Phase-III-Studie zur Injektion von Equecabtagene-Autoleucel bei Patienten mit Lenalidomid-refraktärem R/R-Multiplem Myelom
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM) who have received 1-2 lines of prior therapy. Approximately 240 subjects from China and, in accordance with Japanese regulatory requirements, approximately 20 additional subjects from Japan are planned to be enrolled in this study, for a total of approximately 260 subjects.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accounts for more than 10%-20% of hematologic malignancies worldwide, leading to marrow failure and bone destruction. Equecabtagene Autoleucel (eque-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), which expressed on both mature B lymphocytes and malignant plasma cells. The primary objective for this study is to compare the efficacy of eque-cel versus standard therapy in lenalidomid-refractory RRMM. Subjects will undergo screening with informed consent. After enrollment, randomization will be conducted followed by study treatment in experimental or control group. A follow-up phase will include assessments for safety, efficacy evaluation and pharmacokinetics monitoring (experimental arm) . The duration of this trial is about 6 years.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Beijing, China
- Peking University First Hospital
-
Beijing, China
- Peking University Third Hospital
-
Beijing, China
- Peking Union Medical College Hospital
-
Beijing, China
- People's Hospital of Peking University
-
Beijing, China
- Beijing Chao-Yang Hospital, Capital Medical University
-
Beijing, China
- Beijing GoBoard Boren Hospital
-
Beijing, China
- Fu Xing Hospital, Capital Medical University
-
Changchun, China
- The first hospital of Jilin University
-
Chengdu, China
- West China School of Medicine, West China Hospital of Sichuan University
-
Chongqing, China
- Xinqiao Hospital of AMU
-
Guangzhou, China
- Nanfang Hospital, Southern Medical University
-
Guangzhou, China
- Sun Yat-sen University Cancer Centre
-
Guangzhou, China
- Zhujiang Hospital of Southern Medical University Guangdong
-
Hangzhou, China
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Hangzhou, China
- The Second Affiliated Hospital,Zhejiang University School of Medicine
-
Jinan, China
- Qilu Hospital of Shangdong University
-
Nanchang, China
- The First Affiliated Hospital of Nanchang University
-
Nanjing, China
- Jiangsu Province Hospital
-
Nanjing, China
- Affiliated Drum Tower Hospital, Medical School of Nanjing University
-
Ningbo, China
- The Affiliated People's Hospital of Ningbo University
-
Shanghai, China
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Suzhou, China
- The First Affiliated Hospital of Soochow University
-
Tianjin, China
- Tianjin Medical University General Hospital
-
Tianjin, China
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Wenzhou, China
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, China
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
-
Zhengzhou, China
- Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University
-
-
-
-
-
Fukuoka, Japan
- Kyushu University Hospital
-
Hiroshima, Japan
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
-
Hokkaido, Japan
- Hokkaido University Hospital
-
Hyōgo, Japan
- Hyogo Medical University Hospital
-
Kyoto, Japan
- University Hospital, Kyoto Prefectural University of Medicine
-
Nagoya, Japan
- Nagoya City University Hospital
-
Osaka, Japan
- Kindai University Hospital
-
Osaka, Japan
- The University of Osaka Hospital
-
Tochigi, Japan
- Jichi Medical University Hospital
-
Tokyo, Japan
- Nihon University Itabashi Hospital
-
Tokyo, Japan
- Tokyo Metropolitan Komagome Hospital
-
Tokyo, Japan
- Japanese Red Cross Medical Center
-
Tokyo, Japan
- Institute of Science Tokyo Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 18 to 75 years of age (inclusive of critical values), either gender.
- The subject was previously diagnosed with multiple myeloma and had received 1-2 lines of therapy (including chemotherapy regimens based on proteasome inhibitors and immunomodulatory agents, with each line of therapy receiving at least 1 full cycle ; Documented disease progression during or within 12 months after the most recent anti-myeloma therapy.
- Subjects was lenalidomide-refractory during prior therapy.
- ECOG score of 0 or 1.
- Subjects must have appropriate organ function and meet all of the following laboratory test results before enrollment:
(1) Haematology: Absolute neutrophil count (ANC) ≥1×10^9/L (prior use of granulocyte colony-stimulating factor [G-CSF] support is permitted, but no supportive therapy have been received within 7 days before the laboratory test);Absolute lymphocyte count (ALC) ≥0.3×10^9/L; Platelets ≥50×10^9/L (must not have received platelet transfusion within 7 days prior to laboratory test); Hemoglobin ≥60g/L (must not have received red blood cells transfusion within 7 days prior to laboratory test); (2) Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times of upper limit of normal (ULN); Serum total bilirubin ≤1.5 times of ULN; (3) Renal function: creatinine clearance (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min; (4) Coagulation: fibrinogen≥1.0 g/L; activated partial thromboplastin time (APTT) ≤ 1.5×ULN, pro-thrombin time (PT) ≤ 1.5 × ULN; (5) Pulse oxygen saturation > 91%; (6) Left ventricular ejection fraction (LVEF)≥50%;
6. Subjects agree to use effective tools or drug contraception (excluding safe period contraception) after signing the informed consent form.
7. Subjects must agree to sign or personally sign an ethics committee-approved informed consent form before starting any screening procedures.
Exclusion Criteria:
- Subjects who have used or required long-term immune-suppressive agents (e.g., cyclosporine or systemic steroids) within 14 days prior to enrollment, but the use of physiological substitutes, intermittent, topical, and inhaled steroids is allowed.
- Subjects who have undergone autologous haematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks prior to randomization, or who have previously undergone allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
- Subjects received the following anti-tumor treatments before enrollment: (1)Treated with an immunomodulator within 7 days, or; (2)Received plasma exchange, radiotherapy (except local radiotherapy for myeloma-related bone lesions), cytotoxic chemotherapy, treatment with proteasome inhibitors or other investigational drug within 14 days, or; (3) Treatment with monoclonal antibody for multiple myeloma within 21 days, or; (4) Received other anti-cancer therapy within 14 days or at least 5 half-lives (whichever is shorter) prior to enrollment.
- Significant cardiac disorder.
- Unstable systemic disease as judged by the investigator: including but not limited to severe liver, renal, or metabolic disease requiring medication.
- The subject will not be able to participate in this study if the investigator determines that the subject meets any of the following conditions: (1) Subjects with a history of allergic reaction to the excipient components (DMSO and albumin) of Eque-cel, fludarabine, cyclophosphamide, tocilizumab, or; (2) Subjects who are intolerant to dexamethasone, or; (3) Subjects who have a Life-threatening allergy, hypersensitivity reaction, or intolerance to pomalidomide and/or its excipients (intolerance is defined as discontinuation of prior treatment due to any AE related to pomalidomide) or;
- Have malignancies other than multiple myeloma within 5 years before screening, excluding cervical carcinoma in situ after radical surgery, basal cell or squamous cell skin cancer, localized cancer of prostate after radical prostatectomy, breast ductal carcinoma in situ after radical mastectomy or carcinoma papillary thyroid after radical thyroidectomy.
- Subjects suspected or confirmed to have central nervous system involvement of MM during the screening period.
- Subjects with concurrent plasma cell leukemia(defined as plasma cell proportion in peripheral blood > 5%), Waldenström macroglobulinaemia, POEMS syndrome (polyneuropathy, organ hypertrophy, endocrinopathy, monoclonal protein and skin changes) or primary amyloidosis during screening period.
- Patients with concomitant non-paraskeletal extramedullary soft tissue plasmacytoma (EM-E); patients with multiple paraskeletal extramedullary lesions (EM-B) where the longest diameter of the extramedullary part of any lesion is >3 cm; patients with a single paraskeletal extramedullary lesion (EMB) where the longest diameter of the extramedullary part is >5 cm;.
- Had major surgery within 2 weeks prior to randomization or planned to have surgery within 2 weeks after study treatment (except for subjects who were scheduled to have surgery under local anesthesia).
- Subject with uncontrollable infection.
- Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and hepatitis B virus (HBV) DNA quantification in peripheral blood was higher than the lower limit of detection; hepatitis C virus (HCV) antibody positive and hepatitis C virus (HCV) RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Syphilis test positive; positive cytomegalovirus (CMV) DNA.
- Pregnant or breastfeeding women.
- The subject has a history of central nervous system disorder within 6 months prior to signing the informed consent form.
- Non-hematological toxicity reactions due to prior treatment have not resolved to baseline or ≤ Grade 1 (NCI-CTCAE v5.0, alopecia, Grade 2 peripheral neuropathy were excepted).
- Subjects had other conditions that the investigator considered unsuitable for enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental group
Drug:Equecabtagene Autoleucel Injection |
dosage form: injection, dosage: 1.0×10^6 CAR-T/kg, frequency: single dose.
Andere Namen:
|
|
Aktiver Komparator: Control group
Drug: Daratumumab, Bortezomib, Dexamethasone, Pomalidomide, DPd group: Daratumumab, Pomalidomide, Dexamethasone PVd group: Bortezomib, Dexamethasone, Pomalidomide |
dosage form: injection or subcutaneous injection. For intravenous administration: dose level 16 mg/kg, 28 days/cycle for the DPd regimen
For subcutaneous administration: fixed dose of 1,800 mg. The formulation and route of administration (intravenous or subcutaneous) should be selected according to the clinical practice in the country where the study is conducted. dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen. dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8. dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 months
Zeitfenster: 12 months (+/-3 months) post-randomization
|
The proportion of the first 126 randomized subjects who achieved a complete response (CR) or better, as assessed by Independent Review Committee (IRC), and were MRD-negative (assessed by next-generation flow cytometry [NGF] using the EuroFlow standard operating procedure) at 12 months (+/-3 months) post-randomization. |
12 months (+/-3 months) post-randomization
|
|
Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)
Zeitfenster: up to 5 years from randomization
|
The time from randomization to the first IRC-assessed disease progression or death from any cause. |
up to 5 years from randomization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall MRD negativity rate
Zeitfenster: up to 5 years from randomization
|
The proportion of subjects who achieve MRD negativity at any time after the date of randomization and before the initiation of subsequent therapy |
up to 5 years from randomization
|
|
Duration of MRD negativity
Zeitfenster: up to 5 years from randomization
|
The time from first achievement of MRD negativity to the first subsequent positive MRD status |
up to 5 years from randomization
|
|
Complete Response Rate(CRR)
Zeitfenster: up to 5 years from randomization
|
The proportion of subjects who achieve CR or better post-randomization among all randomized subjects |
up to 5 years from randomization
|
|
Very good partial response or better response (≥VGPR) rate
Zeitfenster: up to 5 years from randomization
|
The proportion of subjects who achieve sCR, CR, or VGPR post-randomization among all randomized subjects |
up to 5 years from randomization
|
|
Overall Response Rate(ORR)
Zeitfenster: up to 5 years from randomization
|
The proportion of subjects who achieve sCR, CR, VGPR, or PR post-randomization among all randomized subjects. |
up to 5 years from randomization
|
|
Duration of Response (DOR)
Zeitfenster: up to 5 years from randomization
|
The time from the first date of initial documented response (≥PR) to the date of first disease progression or death from any cause, whichever occurs first, post-randomization |
up to 5 years from randomization
|
|
Event-Free Survival (EFS)
Zeitfenster: up to 5 years from randomization
|
Time from randomization to the first occurrence of any of the following events: death, disease progression, initiation of a new anti-myeloma therapy, addition of other treatments, or occurrence of fatal or intolerable adverse effects |
up to 5 years from randomization
|
|
Overall Survival(OS)
Zeitfenster: up to 5 years from randomization
|
Defined as the time from randomization to death due to any cause |
up to 5 years from randomization
|
|
Time to Next Treatment(TTNT)
Zeitfenster: up to 5 years from randomization
|
Time from randomization to the initiation of a new subsequent anti-myeloma therapies |
up to 5 years from randomization
|
|
Incidence of Adverse events
Zeitfenster: up to 5 years from randomization
|
Safety Endpoint |
up to 5 years from randomization
|
|
Pharmacokinetic Endpoint-Cmax
Zeitfenster: up to 5 years from Eque-cel infusion
|
The maximum concentration (Cmax) of CAR VCN and BCMA CAR-T in peripheral blood after CAR-T infusion |
up to 5 years from Eque-cel infusion
|
|
Pharmacokinetic Endpoint-Tmax
Zeitfenster: up to 5 years from Eque-cel infusion
|
the time for CAR VCN and BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion |
up to 5 years from Eque-cel infusion
|
|
Pharmacokinetic Endpoint-AUC
Zeitfenster: up to 5 years from Eque-cel infusion
|
Area under the curve of 29, 85, 169 days and the last time point of PK detection (AUC0-29d, AUC0-85d, AUC0-169d, AUC0-last) for CAR VCN; Area under the curve of 29 days (AUC0-29) for BCMA CAR-T. |
up to 5 years from Eque-cel infusion
|
|
Pharmacodynamic Endpoint
Zeitfenster: up to 5 years from Eque-cel infusion
|
The concentration of soluble BCMA in peripheral blood of experimental group at each time point |
up to 5 years from Eque-cel infusion
|
|
Health Related Quality of Life Endpoint
Zeitfenster: up to 5 years from randomization
|
Symptoms, function, and overall HRQoL were collected using the validated Patient-Reported Outcomes (PRO) questionnaire |
up to 5 years from randomization
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Gui Lu Qiu, PhD, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Hauptermittler: Zhen Cai, PhD, First Affiliated Hospital of Zhejiang University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Neubildungen, Plasmazelle
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Hämorrhagische Störungen
- Hämische und lymphatische Krankheiten
- Multiples Myelom
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Polycyclische Verbindungen
- Anorganische Chemikalien
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Steroide, fluoriert
- Schwangerschaften
- Boronsäuren
- Säuren, nicht carboxylisch
- Säuren
- Borverbindungen
- Pyraziner
- Bortezomib
- Dexamethason
- Pomalidomid
- Daratumumab
Andere Studien-ID-Nummern
- CT103AC004
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .